*	OR T1 T2
R1	Has_temporal Arg1:T6 Arg2:T7	
*	OR T5 T6
R3	AND Arg1:T8 Arg2:T9	
R4	AND Arg1:T8 Arg2:T10	
R5	Has_context Arg1:T15 Arg2:T16	
*	OR T14 T15
R6	Has_temporal Arg1:T13 Arg2:T14	
R7	AND Arg1:T21 Arg2:T22	
R8	Has_value Arg1:T22 Arg2:T23	
*	OR T20 T21
*	OR T25 T26
R9	AND Arg1:T24 Arg2:T25	
*	OR T27 T29
R10	Has_qualifier Arg1:T28 Arg2:T27	
*	OR T30 T31
R11	AND Arg1:T24 Arg2:T30	
R13	Has_temporal Arg1:T34 Arg2:T35	
*	OR T37 T39 T40
R14	Has_qualifier Arg1:T37 Arg2:T38	
R16	Has_temporal Arg1:T34 Arg2:T42	
*	OR T44 T45
R17	Subsumes Arg1:T43 Arg2:T44	
*	OR T47 T48
*	OR T49 T50
R18	Has_qualifier Arg1:T43 Arg2:T47	
*	OR T53 T52
*	OR T54 T58 T56 T55 T57
R19	Has_context Arg1:T53 Arg2:T54	
R2	AND Arg1:T4 Arg2:T5	
R20	Has_value Arg1:T61 Arg2:T62	
R21	multi Arg1:T60 Arg2:T61	
*	OR T63 T64
R22	Has_qualifier Arg1:T1 Arg2:T65	
R23	Has_qualifier Arg1:T2 Arg2:T65	
R12	Has_negation Arg1:T28 Arg2:T3	
R24	AND Arg1:T25 Arg2:T28	
R15	Has_negation Arg1:T37 Arg2:T66	
R25	AND Arg1:T34 Arg2:T37	
R26	Has_temporal Arg1:T19 Arg2:T67	
R27	Has_temporal Arg1:T18 Arg2:T68	
R28	AND Arg1:T69 Arg2:T12	
R29	Has_negation Arg1:T5 Arg2:T70	
R30	Has_qualifier Arg1:T43 Arg2:T49	
R31	AND Arg1:T25 Arg2:T26	
T1	Condition 26 40	CNS metastases
T2	Condition 44 70	leptomeningeal involvement
T5	Procedure 144 151	treated
T6	Qualifier 164 179	been stable for
T7	Temporal 180 220	at least six months prior to study start
T4	Condition 92 108	brain metastases
T8	Temporal 238 248	history of
T9	Condition 249 265	brain metastases
T10	Procedure 278 299	head CT with contrast
T12	Condition 359 374	bone metastases
T13	Procedure 432 464	hepatic artery chemoembolization
T14	Temporal 465 489	within the last 6 months
T15	Temporal 491 500	one month
T16	Observation 514 547	other sites of measurable disease
T18	Procedure 597 627	radioactive directed therapies
T19	Drug 676 686	epothilone
T20	Condition 706 727	peripheral neuropathy
T21	Condition 731 750	unresolved diarrhea
T22	Measurement 764 769	Grade
T23	Value 751 763;770 771	greater than 1
T24	Condition 787 815	severe cardiac insufficiency
T25	Drug 832 840	Coumadin
T26	Drug 850 876	warfarin-containing agents
T27	Qualifier 899 907	low dose
T28	Drug 908 916	warfarin
T29	Multiplier 918 930	1 mg or less
T30	Device 955 972	in-dwelling lines
T31	Device 955 966;976 981	in-dwelling ports
T34	Condition 1037 1055	another malignancy
T35	Temporal 1056 1091	within 5 years prior to study entry
T37	Condition 1118 1142	non-melanoma skin cancer
T38	Qualifier 1099 1117	curatively treated
T39	Condition 1144 1159	prostate cancer
T40	Condition 1164 1187	cervical cancer in situ
T42	Temporal 1026 1036	history of
T43	Condition 1240 1262	uncontrolled infection
T44	Condition 1273 1281	abcesses
T45	Condition 1285 1293	fistulae
T47	Qualifier 1203 1209	active
T48	Qualifier 1213 1222	suspected
T49	Qualifier 1223 1228	acute
T50	Qualifier 1232 1239	chronic
T52	Condition 1322 1341	psychiatric illness
T53	Condition 1311 1318;1334 1341	medical illness
T54	Observation 1353 1367	preclude study
T55	Observation 1371 1387	informed consent
T56	Observation 1406 1439	noncompliance to medical regimens
T57	Mood 1443 1452;1470 1504	inability to return for all scheduled visits
T58	Mood 1456 1503	unwillingness to return for all scheduled visit
T60	Condition 1506 1510	HIV+
T61	Measurement 1506 1509	HIV
T62	Value 1509 1510	+
T63	Condition 1521 1529	Pregnant
T64	Condition 1533 1542	lactating
T65	Qualifier 14 25	symptomatic
T3	Negation 877 898	with the exception of
T66	Negation 1092 1098	except
T33	Non-representable 983 1025	Patients taking any experimental therapies
T67	Temporal 652 662	previously
T68	Temporal 573 583	previously
T69	Multiplier 382 416	only site(s) of measurable disease
T70	Negation 110 116	unless
